Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melapuldencel-T in metastatic melanoma
NCT01875653Phase 3Terminated
- Sponsor
- Lisata Therapeutics
- Start
- Oct 2014
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Intus in melanoma (2 arms), sponsored by Lisata Therapeutics. Primary endpoint: Overall Survival at 52 months. Started Oct 2014; status: terminated.
02
Drugs
Intus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01875653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01875653.